Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

ImmunoGen shares jump after Barclays raises price target of biotech firm

Published 06/09/2023, 09:42 PM
Updated 06/09/2023, 09:42 PM
© Reuters

© Reuters

Investing.com -- Shares in ImmunoGen (NASDAQ:IMGN) jumped in early trading on Friday after analysts at Barclays raised their price target for the stock to $20 from $9, citing positive commentary around the biotech company's ovarian cancer treatment.

In a note to clients, the Barclays analysts said data presented by the firm for its Elahere ovarian cancer drug at the recent American Society of Clinical Oncology conference were "well received," adding that some observers believe the treatment can be "practice changing."

ImmunoGen previously announced in May that a late-stage trial showed that Elahere helped extend the lives of patients without the cancer worsening, particularly when compared to chemotherapy. Analysts at Truist Securities told Reuters at the time the result was a "home run" for ImmunoGen and all but removes doubt that the drug candidate will eventually receive approval from U.S. drug regulators.

Elsewhere on Friday, ImmunoGen announced updated interim results of a Phase 2 trial of its pivekimab for people with a rare blood cancer. The co-investigator of the study said there was "impressive anti-tumor activity and durable responses" in both frontline and relapsed patients, adding that pivekimab has the potential to be a "promising, novel option for this challenging disease."

When measuring from Thursday's closing price, shares in ImmunoGen have now climbed 217% so far this year.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.